Quantum BioPharma Ltd.(QNTM)Earnings, Financials & Key Ratios
QNTM•NASDAQ
$3.73
Price updated Jun 27, 2026
AboutQuantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.Show more
- Revenue$0
- EBITDA-$15M+5.7%
- Net Income-$26M-84.3%
- EPS (Diluted)-8.11+35.1%
- ROE-337.02%-177.0%
QNTM Price & Volume
Quantum BioPharma Ltd. (QNTM) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Development Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall
"Quantum BioPharma remains a pre-commercial entity characterized by a total absence of operational revenue and a reliance on external financing to sustain its clinical-stage pipeline. The company's financial health is increasingly precarious, with equity levels collapsing to $597.2K as of 2026Q1, while non-core strategic investments introduce significant volatility and potential impairment risks. Investors should remain cautious as the firm faces an imminent liquidity shortfall, evidenced by a current ratio of 0.63 and a persistent quarterly cash burn that threatens the continuity of its research programs."
Verdict Logic
the company's precarious liquidity position, highlighted by a current ratio of 0.63 and a dwindling cash balance of $4.4 million, suggests a high probability of further shareholder dilution or insolvency.
QNTM Growth Metrics
Quantum BioPharma Ltd. (QNTM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-48.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM61.4%
Return on Capital
10 Years-98.26%
5 Years-116.75%
3 Years-148.21%
Last Year-197.02%
QNTM Recent Earnings
Quantum BioPharma Ltd. (QNTM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$3.06-524.0%
$0.49
Rev
—
$4M
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.71+30.5%
$1.02
Rev
—
$2M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$1.25-525.0%
$0.20
Rev
—
$889,591
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$3.23-1800.0%
$0.17
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $3.06vs $0.49-524.0% | —vs $4M |
| Q2 2026 | Mar 26, 2026 | $0.71vs $1.02+30.5% | —vs $2M |
| Q4 2025 | Nov 7, 2025 | $1.25vs $0.20-525.0% | —vs $889,591 |
| Q3 2025 | Aug 6, 2025 | $3.23vs $0.17-1800.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Quantum BioPharma Ltd. (QNTM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.73 | $16.74M | -0.46 | — | — | -337.02% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $1.72 | $33.84M | -1.23 | — | — | -318.08% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $14.82 | $1.42B | -4.81 | — | — | -151.02% | — |
Compare QNTM vs Peers
Quantum BioPharma Ltd. (QNTM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when QNTM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QNTM Frequently Asked Questions
Quantum BioPharma Ltd. (QNTM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is QNTM profitable?
Quantum BioPharma Ltd. (QNTM) reported a net loss of $31.0M for fiscal year 2025.
Dividend & Returns
What is QNTM's return on equity?
Quantum BioPharma Ltd. (QNTM) has a return on equity (ROE) of -337.0%. Negative ROE indicates the company is unprofitable.
What is Quantum BioPharma Ltd.'s free cash flow?
Quantum BioPharma Ltd. (QNTM) had negative free cash flow of $5.6M in fiscal year 2025, likely due to heavy capital investments.